Literature DB >> 1425677

Purification of human leukotriene C4 synthase from dimethylsulfoxide-differentiated U937 cells.

D W Nicholson1, M W Klemba, D M Rasper, K M Metters, R J Zamboni, A W Ford-Hutchinson.   

Abstract

Human leukotriene C4 (LTC4) synthase was purified > 10000-fold from dimethylsulfoxide-differentiated U937 cells. Steps included: (a) solubilization of membrane-bound LTC4 synthase from microsomal membranes by the anionic detergent taurocholate; (b) successive anion-exchange chromatography steps in the presence of taurocholate plus Triton X-100 (primary anion exchange) then taurocholate plus n-octyl glucoside (secondary anion exchange); and (c) LTC2-affinity chromatography on a matrix that was constructed by first biotinylating synthetic LTC2 then immobilizing the biotinylated LTC2 on streptavidin agarose. The purification of human LTC4 synthase was enabled by the finding that LTC4 synthase activity in preparations enriched > 500-fold was absolutely dependent on the presence in LTC4 synthase incubation mixtures of divalent cations (specifically Mg2+) and phospholipids (specifically phosphatidylcholine), and that reduced glutathione, which was required at 2-4 mM for stabilization of LTC4 synthase, irreversibly inactivated the enzyme when present at > or = 5 mM during freeze/thaw cycles. The > 10000-fold purified LTC4 synthase preparation was comprised of three polypeptides having molecular masses of 37.1, 24.5 and 18.0 kDa. An 18-kDa polypeptide in both microsomal membranes and in the LTC2-affinity purified fraction was specifically labelled by a radioiodinated LTC4 photoaffinity probe (azido 125I-LTC4). The Km values in the LTC2-affinity purified preparation for reduced glutathione and LTA4 were 1.83 mM and 19.6 microM (respectively), closely resembling the Km values in isolated human blood monocytes. The Vmax of LTC2-affinity purified LTC4 synthase was 2-4 mumol LTC4 formed .min-1 x mg-1.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1425677     DOI: 10.1111/j.1432-1033.1992.tb17341.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  8 in total

Review 1.  Leukotriene antagonists and inhibitors as modulators of IgE-mediated reactions.

Authors:  A W Ford-Hutchinson
Journal:  Springer Semin Immunopathol       Date:  1993

Review 2.  LTC4 synthase. Enzymology, biochemistry, and molecular characterization.

Authors:  J F Penrose
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

3.  Purification to homogeneity and the N-terminal sequence of human leukotriene C4 synthase: a homodimeric glutathione S-transferase composed of 18-kDa subunits.

Authors:  D W Nicholson; A Ali; J P Vaillancourt; J R Calaycay; R A Mumford; R J Zamboni; A W Ford-Hutchinson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

Review 4.  Regulation of leukotriene biosynthesis.

Authors:  A W Ford-Hutchinson
Journal:  Cancer Metastasis Rev       Date:  1994-12       Impact factor: 9.264

5.  Expression cloning of a cDNA for human leukotriene C4 synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A4.

Authors:  B K Lam; J F Penrose; G J Freeman; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-02       Impact factor: 11.205

6.  Molecular cloning and expression of human leukotriene-C4 synthase.

Authors:  D J Welsch; D P Creely; S D Hauser; K J Mathis; G G Krivi; P C Isakson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

7.  Human epidermis transforms exogenous leukotriene A4 into peptide leukotrienes: possible role in transcellular metabolism.

Authors:  L Iversen; P Kristensen; B Grøn; V A Ziboh; K Kragballe
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

8.  Selective inhibition of MDR1 P-glycoprotein-mediated transport by the acridone carboxamide derivative GG918.

Authors:  A Wallstab; M Koester; M Böhme; D Keppler
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.